What is NICE?

NICE guidance helps health and social care professionals deliver the best possible care based on the best available evidence. This guidance supports healthcare professionals and others to make sure that the care they provide is of the best possible quality and offers the best value for money. The guidance is for the NHS, local authorities, charities, and anyone with a responsibility for commissioning or providing healthcare, public health or social care services. We also support these groups in putting our guidance into practice.

Thursday 4 July 2013

NICE plans to recommend a new treatment for children with bipolar disorder

NICE, the health and social care guidance body, has issued new draft guidance proposing to recommend aripiprazole (Abilify, Otsuka Pharmaceuticals Europe), for treating moderate to severe manic episodes in adolescents aged 13 and older with bipolar I disorder1.
Commenting on the draft guidance, Professor Carole Longson, Director, Centre for Health Technology Evaluation, said. “Bipolar disorder is a serious mental health condition which is characterised by episodes of mania and depression. During a manic episode, the young person usually experiences irritability, poor concentration, little need for sleep and poor temper control. They may also feel over-confident and be driven to take unnecessary risks.
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)